Pascal A.T. Baltzer is an associate professor and section head of urogenital imaging at the Medical University of Vienna, Austria. He is an executive board member of the European Society of Breast Imaging (EUSOBI) and serves as the EUSOBI representative within the Scientific committee of the European Society of Radiology (ESR). Dr. Baltzer is also spokesman of the urogenital working group of the Austrian X-ray society. Since July 2020 he took over the position as Editor-in-Chief of the European Journal of Radiology.

Dr. Baltzer was trained by the late Dr. Werner Alois Kaiser, MRI-pioneer and inventor of breast MRI, at the university hospital of the Friedrich-Schiller-University of Jena, Germany. At that time, the department including its dedicated MRI research center was a heaven for technically interested young radiologists. After his board certification, he served as consultant and modality manager for breast imaging before moving to Vienna, Austria and taking over the section lead in urogenital radiology.

In recent years, Dr. Baltzer´s research increasingly focused on clinical oncological Gender Imaging using multiparametric MRI including MR-spectroscopy, multi-tracer PET and hybrid combinations thereof. Current projects include multinational and multidisciplinal efforts to establish imaging biomarkers and A.I. based methods in clinical practice and evidence-based integrated diagnostics.

Eleven years ago, I started my career in Nuclear Medicine, as a specialist in the Nuclear Medicine Unit of Veneto Institute of Oncology IOV – IRCCS in Padua, Italy. Currently, I am working as a researcher at the University of Padua. I completed my residency program in Nuclear Medicine in 2009 (summa cum laude) at the University of Naples “Federico II” and completed my Ph.D. program in Molecular Imaging in 2012. Moreover, in 2016, I attended a Master in Health Technology Assessment (HTA) at University Cattolica of Rome. During my ten years at IOV – IRCCS, I have actively participated in clinical studies, as principal investigator, and research conferences, as an organizer. Also, I have published more than 150 articles, and I have been involved in the day-to-day activities of the nuclear medicine and diagnostic radiology laboratories, as well as multidisciplinary meetings for patient management. I am keen to collaborate with different realities inside and outside Italy.

My experience in two different American Hospitals, the Memorial Sloan Kettering Cancer Center in New York city (NY) and the Mayo Clinic in Rochester (MN), have been very useful to me. Moreover, from 2012 I have been actively involved in the European Association of Nuclear Medicine by participating as the Secretary of the Translational and Molecular Imaging and Therapy committee and from 2017, I have been included into the board of the Italian Association of Nuclear Medicine. I am used to being invited as a speaker in the annual congress of American Society of nuclear medicine (SNNMI). I am currently serving as the Editor in Chief of the Clinical and Translational Imaging, the official journal of the Italian Association of Nuclear Medicine.

Juhani Knuuti, MD, PhD is director and professor of Turku PET Centre, University of Turku and Turku University Hospital, Finland.

Professor Knuuti’s main research field is noninvasive imaging especially using PET, SPECT, echocardiography, MRI and CT. The main research focus has been on cardiovascular diseases especially coronary artery disease and heart failure. In these conditions, the focus has been in understanding the physiology and pathophysiology of these diseases as well in developing new tests for diagnosis and therapy guidance.

He has 823 publications, of which 553 are original articles and reviews. His H-index is 79 and the publications have been cited 51 630 times and 93 times per item.

He has worked actively in European Society of Cardiology (ESC) and European Association of Nuclear Medicine (EANM) working groups, councils and committees. He has contributed to large number clinical guidelines and chaired two ESC clinical guidelines.

He has arranged several international congresses and acts as member of editorial boards of several scientific journals. He is currently also Senior Associate Editor of European Heart Journal – Cardiovascular Imaging.

Prof. Dr. Klaus Strobel ist dual board certified in Radiology and Nuclear Medicine and currently head of Nuclear Medicine at Cantonal Hospital Lucerne, Switzerland. He reports on hybrid imaging studies since 2004 daily. For the last five years he was vice president of the bone & joint committee of the EANM. His main research interest is hybrid imaging, especially bone and joint SPECT/CT in orthopedic applications. He served as teacher for ESMIT courses and IDKD Davos.

Giorgio Treglia, PD MD MSc(HTA), is a senior consultant of Nuclear Medicine at the Imaging Institute of Southern Switzerland (Bellinzona and Lugano, CH), and Coordinator of the Research and Innovation Service at the Ente Ospedaliero Cantonale (Bellinzona, CH). He holds an academic position as Private Docent of Nuclear Medicine at the University of Lausanne (Lausanne, CH).

His main research field is evidence-based imaging with special focus on hybrid imaging in inflammatory/infectious diseases and oncology. He is an expert of systematic reviews and meta-analyses on PET/CT with more than 330 full-text articles published as author or co-author. He is currently listed by Expertscape among the top 3 experts worldwide in the following categories: multimodal imaging, PET, nuclear medicine, radionuclide imaging.

He is an active member of the European Association of Nuclear Medicine (EANM), with engagement in several working groups, councils or committees (current member of the EANM Inflammation and Infection Committee and the EANM Scientific Program Council). He is also associate collaborator of Cochrane Switzerland, member of the PET working group of the Swiss Society of Nuclear Medicine, member of the faculty of the European School of Molecular Imaging and Therapy (ESMIT) and editorial board member for several international scientific journals.

More info will follow soon.

Thomas Beyer holds a PhD in Physics and is co-developer of combined PET/CT imaging systems. He has a background in research and project management in academia and imaging industry.

Thomas graduated in Physics from the Leipzig University (Germany) and got his PhD in Medical Physics from Surrey University (UK). During his US-based studies he became involved in the development and clinical testing of the first PET/CT prototype (1992-2000) before joining Siemens/CTI PET Systems as an International PET/CT specialist.

In 2002 he became a Research Associate in Nuclear Medicine and Radiology and PET/CT project manager at Essen University Hospital (Germany). In 2006 he became Teaching Professor (Priv.-Doz.) for Experimental Nuclear Medicine at Essen, and joined timaq medical imaging Inc, a Zurich-based Imaging CRO. In 2007 Thomas moved to Philips Medical Systems as International Manager Clinical Science Nuclear Medicine. In 2008 he set up a Zurich-based consulting company for expert advise in cross-modality imaging and applications. He is appointed full professor of Physics of Medical Imaging at the Medical University of Vienna from March 2013.

Thomas is a member of various national and international Medicine organizations, a founding member of the European Association of Nuclear Medicine (EANM) Physics Committee, the European Society of Hybrid Imaging (ESHI) and past Head of the New Technology working group at the Association of Imaging Producers and Equipment Suppliers (AIPES).

Prof. Dr. Roger Schibli is full professor at the Department of Chemistry and Applied Biosciences (ETH Zurich) since 2010, and Laboratory Head at the Paul Scherrer Institute (PSI). He is leading the Center for Radiopharmaceutical Science (CRS), a joint endeavor between the ETH Zurich, the Paul Scherrer Institute and the University Hospital Zurich. Prof. Schibli studied Chemistry at the University of Basel. His early research was dedicated to the development of new organometallic complexes of technetium and rhenium for potential radiopharmaceutical application. He spent two years at the University of Missouri-Columbia as a post-doctoral fellow. He was appointed assistant professor for Therapeutics Technologies at the Institute of Pharmaceutical Sciences (ETH Zurich) in 2004 and was tenured in 2009.

Prof. Schibli’s research is directed towards targeted tumor diagnosis and therapy using radiolabeled compounds. His lab emphasizes on the development of new radionuclides, identification of novel targeting molecules, and their biological and pharmacological characterization and optimization. CRS performs “bench-to-bedside” research and has the capacity to translated novel radiopharmaceutical drug candidates into clinical testing. A ¹⁷⁷Lu-labeled peptides targeting the cholecystokinin-2 receptor developed in his lab was recently licensed to Debiopham™.  Besides, Prof. Schibli is a co-founder of the spin-off company ARARIS Biotech, developing site-specially modified ADCs.